Welcome to LookChem.com Sign In|Join Free

CAS

  • or

17422-54-7

Post Buying Request

17422-54-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

17422-54-7 Usage

General Description

8-nitro-2,3,4,5-tetrahydro-1H-benzo[b]azepine is a chemical compound with the molecular formula C11H12N2O2. It belongs to the class of benzoazepines and contains a nitro group at the 8th position. 8-nitro-2,3,4,5-tetrahydro-1H-benzo[b]azepine has potential pharmacological properties and has been studied for its potential as an anti-inflammatory and analgesic agent. The molecular structure of 8-nitro-2,3,4,5-tetrahydro-1H-benzo[b]azepine makes it a promising candidate for further research in the development of new therapeutic drugs. Additionally, it may have other biological activities that could be of interest to the pharmaceutical industry.

Check Digit Verification of cas no

The CAS Registry Mumber 17422-54-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,4,2 and 2 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 17422-54:
(7*1)+(6*7)+(5*4)+(4*2)+(3*2)+(2*5)+(1*4)=97
97 % 10 = 7
So 17422-54-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2O2/c13-12(14)9-5-4-8-3-1-2-6-11-10(8)7-9/h4-5,7,11H,1-3,6H2

17422-54-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 8-nitro-2,3,4,5-tetrahydro-1H-1-benzazepine

1.2 Other means of identification

Product number -
Other names I14-9473

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:17422-54-7 SDS

17422-54-7Relevant articles and documents

Potent and Selective Inhibitors of 8-Oxoguanine DNA Glycosylase

Tahara, Yu-Ki,Auld, Douglas,Ji, Debin,Beharry, Andrew A.,Kietrys, Anna M.,Wilson, David L.,Jimenez, Marta,King, Daniel,Nguyen, Zachary,Kool, Eric T.

supporting information, p. 2105 - 2114 (2018/02/19)

The activity of DNA repair enzyme 8-oxoguanine DNA glycosylase (OGG1), which excises oxidized base 8-oxoguanine (8-OG) from DNA, is closely linked to mutagenesis, genotoxicity, cancer, and inflammation. To test the roles of OGG1-mediated repair in these pathways, we have undertaken the development of noncovalent small-molecule inhibitors of the enzyme. Screening of a PubChem-annotated library using a recently developed fluorogenic 8-OG excision assay resulted in multiple validated hit structures, including selected lead hit tetrahydroquinoline 1 (IC50 = 1.7 μM). Optimization of the tetrahydroquinoline scaffold over five regions of the structure ultimately yielded amidobiphenyl compound 41 (SU0268; IC50 = 0.059 μM). SU0268 was confirmed by surface plasmon resonance studies to bind the enzyme both in the absence and in the presence of DNA. The compound SU0268 was shown to be selective for inhibiting OGG1 over multiple repair enzymes, including other base excision repair enzymes, and displayed no toxicity in two human cell lines at 10 μM. Finally, experiments confirm the ability of SU0268 to inhibit OGG1 in HeLa cells, resulting in an increase in accumulation of 8-OG in DNA. The results suggest the compound SU0268 as a potentially useful tool in studies of the role of OGG1 in multiple disease-related pathways.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

-

, (2012/04/23)

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 17422-54-7